Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has recently appointed Winston Kung to its board of directors, effective as of August 16, 2024. Kung, who will also chair the audit committee, brings over 20 years of leadership experience across life sciences and investment banking to the company.
Prior to joining Corbus, Kung served as the Chief Financial Officer of Arrivent Biopharma, a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics. He also held significant positions at PMV Pharmaceuticals, Celgene, Citigroup's global healthcare investment banking group, and Lehman Brothers' global mergers and acquisition group. Kung earned his M.B.A from Harvard Business School and a B.A. in Biology and International Relations from Brown University.
In addition to Kung's appointment, the company also announced the resignation of Avery "Chip" Catlin from the board and as chair of the audit committee after serving on the Corbus board for over ten years.
Corbus Pharmaceuticals, headquartered in Norwood, Massachusetts, is an oncology company with a diversified portfolio committed to bringing innovative scientific approaches to well-understood biological pathways. The company's pipeline includes CRB-701, CRB-601, and CRB-913, targeting the expression of nectin-4 on cancer cells, blocking the activation of TGFβ expressed on cancer cells, and the treatment of obesity, respectively.
As a result of these changes, investors and stakeholders will be closely monitoring the impact of the new appointment and the resignation on the company's strategic direction and financial performance in the upcoming periods. Following these announcements, the company's shares moved -0.7%, and are now trading at a price of $57.79. For the full picture, make sure to review Corbus Pharmaceuticals's 8-K report.
